PMV Pharmaceuticals announces first patient dosed in Phase 2 PYNNACLE trial

PMV Pharmaceuticals announced that the first patient has been dosed in the registrational, tumor-agnostic PYNNACLE Phase 2 trial of rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type. Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets mutated p53 Y220C proteins in solid tumors. “Building upon our promising Phase 1 data, we are pleased to announce the dosing of our first patient in the global Phase 2 PYNNACLE trial of rezatapopt as a monotherapy in patients with advanced solid tumors harboring a TP53 Y220C mutation and KRAS wild-type,” said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. “This pivotal trial is a testament to PMV’s commitment to developing new treatment options for patients with advanced solid tumors with a significant unmet medical need.”